Proroxan

Proroxan
Clinical data
Other names	Pyrroxane, Pirroksan
Legal status
Legal status	Rx in Russia;
Identifiers
	IUPAC name 1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-3-(3-phenylpyrrolidin-1-yl)propan-1-one;
CAS Number	33743-96-3;
PubChem CID	36303;
UNII	T5WT3QN49G;
KEGG	D05641;
CompTox Dashboard (EPA)	DTXSID9046285 ;
Chemical and physical data
Formula	C21H23NO3
Molar mass	337.419 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN(CC1C2=CC=CC=C2)CCC(=O)C3=CC4=C(C=C3)OCCO4;
	InChI InChI=1S/C21H23NO3/c23-19(17-6-7-20-21(14-17)25-13-12-24-20)9-11-22-10-8-18(15-22)16-4-2-1-3-5-16/h1-7,14,18H,8-13,15H2; Key:GZIISXIDAZYOLI-UHFFFAOYSA-N;

Proroxan (INN; also known as pyrroxane and pirroksan) is a pharmaceutical drug used as an antihypertensive and in the treatment of Ménière's disease, motion sickness, and allergic dermatitis.^[1]^[2]

Proroxan is a non-selective alpha-blocker (α-adrenoreceptor antagonist).^[1]

Proroxan was developed in the 1970s at the Institute of Toxicology of the USSR Ministry of Health^[3] and today is primarily used in Russia. Though originally developed as an antihypertensive, its use can lead to a decrease in alcohol and drug consumption. Currently proroxan is used almost exclusively in psychiatry, narcology, and neurology.^[3]

References

^ ^a ^b "Proroxan hydrochloride". Inxight Drugs. National Institutes of Health.
^ "ПРОРОКСАН (PROROXAN) ОПИСАНИЕ". vidal.ru.
^ ^a ^b Shabanov PD (2020). "Clinical pharmacology of pyrroxane (proroxane)". Reviews on Clinical Pharmacology and Drug Therapy (in Russian). 18 (4): 335–350. doi:10.17816/RCF184335-350. S2CID 234440112.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[Inxight-1] "Proroxan hydrochloride". Inxight Drugs. National Institutes of Health.

[2] "ПРОРОКСАН (PROROXAN) ОПИСАНИЕ". vidal.ru.

[Shabanov-3] Shabanov PD (2020). "Clinical pharmacology of pyrroxane (proroxane)". Reviews on Clinical Pharmacology and Drug Therapy (in Russian). 18 (4): 335–350. doi:10.17816/RCF184335-350. S2CID 234440112.

[1]

[2]

[3]